| |
NEWLY AVAILABLE, NEWLY APPROVED
Osteoconductive Suture
Anchor
|
ArthroCare® Corp. has launched its
new DoublePlay implant, a new suture
anchor device intended for fixation
of soft tissue to bone in surgical procedures
such as rotator cuff repair. The company
states that the DoublePlay implant is
unique in terms of design and material.
The DoublePlay device is a fully threaded
anchor and features an “eyeless” design
that eliminates the risk of eyelet
breakage, the most common mode of
failure in standard absorbable anchors.
ArthroCare notes that DoublePlay is
manufactured from a proprietary composite
material, the first composite to be
used in sports medicine with clinically
proven osteoconductivity and replacement
by bone.
DoublePlay has received US Food and
Drug Administration clearance for
fixation of suture to bone in the
shoulder, foot, ankle, knee, hand,
wrist, elbow, and pelvis. The device
is preloaded with Magnum wire.
For more information, contact
ArthroCare
7500 Rialto Boulevard, Building Two, Suite 100
Austin, Texas 78735
phone (512) 391-3900; fax (512) 391-3901
www.ArthroCare.com |
Digital Image
Distribution
|
Orthocrat Ltd, a leading provider of orthopedic preoperative planning software,
has introduced OrthoFlow, a management tool that is designed to enable orthopedic
surgeons to distribute their patients’ digital images to clinic rooms
in less time and with less administrative hassle. Integrated with major
PACS, OrthoFlow’s solution is aimed at increasing efficiency while ensuring
the highest level of security and privacy for patient information.
After an initial log-in at a diagnostic workstation, surgeons can upload and
review digital images and send them to a specific patient examination room.
Once the surgeon enters the examination room, the selected digital images are
pulled up on the screen with a simple swipe of an HID reader connected to the
computer. This eliminates the need to log into the PACS again and repeat
the search for data, thus saving time.
The company notes that OrthoFlow also adds a high level of security and privacy
for patients during clinical visits. OrthoFlow’s embedded HID reader
locks the computer screen while patients wait in the examination room, ensuring
that no one except the surgeon can unlock the screen and view the file.
For more information, contact
Orthocrat
phone (866) 717-0272
www.orthocrat.com
|
FDA Broadens Reclast
Indication
|
The US Food and Drug Administration (FDA) has broadened the US indication for
once-yearly Reclast® (zoledronic acid) Injection to include the prevention
of new clinical fractures in patients who have recently had a low-trauma hip
fracture.1
The FDA decision is based on safety and efficacy data from the landmark Recurrent
Fracture Trial, published in The New England Journal of Medicine, showing a
significant 35% reduction in the risk of new clinical fractures in patients
treated with Reclast.2 The Recurrent Fracture Trial
involved more than 2,100 men and women aged 50 and older with osteoporosis
who had experienced a recent
low-trauma hip fracture.2 Results showed that Reclast increased bone mineral density and reduced the risk
of new clinical fractures by 35% compared with patients treated with placebo.2 The risk of new spine fractures was reduced by 46%.2 The incidence of all-cause
mortality was 9.6% in the Reclast group and 13.3% in the placebo group.2
The active ingredient in Reclast is zoledronic acid 5 mg administered once a
year.1
For more information about Reclast, contact
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
phone 866-RECLAST
www.reclast.com
References
|
|
